ÂÜÀòÂÒÂ×

Mark Stockdale is a seasoned professional in the field of synthetic biology and biopharmaceuticals, currently serving as the Senior Director of Strategic Alliance at Asimov since February 2020. With extensive experience in strategic alliances and business development, Mark has contributed to transforming Asimov's capabilities in partner laboratories. Prior roles include Director at Galvanize Bio Ltd., and Amalgamator of Business and Biology at Solentim, where responsibilities involved advancing solutions for cell and gene therapies. Mark's prior experience encompasses various leadership and scientific roles at Horizon Discovery, Lonza, Cyclacel Ltd, Systems Biology Laboratory UK Ltd, and Pfizer Ltd, where significant work in gene editing, cell line development, and virology was conducted. Mark holds a BSc in Biochemistry with Applied Molecular Biology from The University of Manchester, obtained in 2003.